$RIBT Institutional Investors Lead Shift in Ricebran

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
240
$RIBT Institutional Investors Lead Shift in Ricebran Technologies (NASDAQ:RIBT) Sentiment

September 18, 2018

http://fanob.com/2018/09/18/institutional-inv...sentiment/

Ricebran Technologies (NASDAQ:RIBT) institutional sentiment increased to 2 in 2018 Q2. Its up 0.71, from 1.29 in 2018Q1. The ratio is more positive, as 12 active investment managers increased and opened new positions, while 6 sold and reduced their holdings in Ricebran Technologies. The active investment managers in our partner’s database now hold: 2.15 million shares, up from 937,360 shares in 2018Q1. Also, the number of active investment managers holding Ricebran Technologies in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 3 Increased: 7 New Position: 5.

RiceBran Technologies processes and markets healthy, natural, and nutrient dense products derived from raw rice bran. The company has market cap of $72.28 million. The firm makes and distributes stabilized rice bran in various granulations with other products and derivatives. It currently has negative earnings. It also extracts crude rice bran oil and defatted rice bran from rice bran, which are processed into refined rice bran oil, as well as compounded animal nutrition products for horses, cows, swine, sheep, and poultry; and various food and animal nutrition products derivatives and co-products.

The stock decreased 2.61% or $0.08 during the last trading session, reaching $2.98. About 106,012 shares traded. RiceBran Technologies (NASDAQ:RIBT) has risen 177.57% since September 18, 2017 and is uptrending. It has outperformed by 161.95% the S&P500.

Perkins Capital Management Inc holds 0.26% of its portfolio in RiceBran Technologies for 169,000 shares. Bard Associates Inc owns 48,275 shares or 0.05% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 667 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Cannell Peter B & Co Inc, a New York-based fund reported 42,408 shares.

Since January 1, 0001, it had 7 insider buys, and 0 insider sales for $1.58 million activity.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

USDA Under Scrutiny as ASPCA Reports on Puppy Mill Violations

Updated Category News Views 322

ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....

Continue Reading
PowerReviews Unveils Partner Program to Amplify UGC Value

Updated Category News Views 1653

PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...

Continue Reading
Turnspire Capital Partners Expands Portfolio with GHP Group

Updated Category News Views 81

Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...

Continue Reading
MPI Corporation Launches Groundbreaking 250 GHz Probe System

Updated Category News Views 187

Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...

Continue Reading
Passage Bio's Gene Therapy Strategy: Hope for Dementia Treatments

Updated Category News Views 76

Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...

Continue Reading